Fig. 5

(A) Schematic illustration of the incubation of S.oneidensis MR-1 and subsequently one-pot large-scale microbial synthesis of FDA-approved Prussian blue MOFs. (B) Schematic illustration of the biological precipitation of PB MOFs coated S. oneidensis MR-1 hybrid (S. oneidensis-MOFs). (C) Schematic illustration of the mitochondria-targeting MiBaMc system-induced ICD combined with aPDL1 for enhanced tumor immunotherapy. (D) Quantitative analysis of the matured DCs, the CD3 + CD8 + cytotoxic Tcells and CD3 + CD4 + helper Tcells as a percentage of CD3 + lymphocytes based on flow cytometric results. (n = 3mice). (E) 4T1 (the former) and MC38 (the latter) tumor volumes of different groups were measured every 2 days (n = 5 mice). Statistical analysis was conducted by one way ANOVA with Tukey’s tests. n.s. represents none of significance, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Reproduced with permission [157]. Copyright 2023, Nature. (F) Schematic diagram of the synthesis and preparation process of PB/PM/HRP/Apt biomimetic nanocomposite and the mechanism of collaborative therapy. (G) The relative content changes of IFN-γ, TNF-α, IL-6 and granzyme B in tumor tissues. (H) The tumor growth curves of 4T1 solid tumor-bearing mice monitored every 2 days after different treatments (n = 5), and representative digital photographs of dissected tumors. (I) H&E staining images of 4T1 solid tumor sections obtained after injection of PBS, PBS + Laser, PB/PM/HRP/Apt and PB/PM/HRP/Apt + Laser. Scale bar: 100 μm. Reproduced with permission [162]. Copyright 2023, Frontiers